Phase II Clinical Trial of KJ101in the Treatment of Deep II Degree Burns

Phase 2 Recruiting 144 enrolled Shanghai Bao Pharmaceuticals Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This multicentre, randomised, double-blind, dose-finding, active- and placebo-controlled Phase II clinical trial will evaluate the safety, efficacy, pharmacokinetic profile, and immunogenicity of KJ101 for the debridement of deep second-degree burns. The trial will provide supporting evidence for subsequent Phase III trials.

Timeline

Start: 2025-06-16
Primary completion: 2026-03-18
Completion: 2026-08-29

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Chymotrypsin	Protein / enzyme biologic	800 unknown	Other
Subject	KJ101	Unknown	800 unknown	Other
Subject	KJ101	Unknown	1200 unknown	Other

Indications

No indication recorded.